Europe's pharmaceutical sector, long considered a cornerstone of its global competitiveness, faces mounting challenges in securing the supply of critical medicines. A combination of geopolitical shifts, global health crises and industrial dependencies has exposed structural vulnerabilities in the supply chain. The European Commission's proposed Regulation (COM(2025) 102) aims to fortify the resilience of this essential sector. It outlines a comprehensive framework to address shortages, diversify supply sources, strengthen manufacturing capacity and ensure equitable access to medicines of critical and common interest across the Union. This initiative is designed not only to protect public health but also to reinforce Europe’s strategic autonomy in healthcare.
Structural Vulnerabilities and Supply Chain Dependencies
Europe's reliance on external sources for essential pharmaceutical components has long been a latent concern. However, crises such as the COVID-19 pandemic and the war in Ukraine brought these weaknesses to the forefront. A significant portion of active substances used in medicines are now produced outside the EU, particularly in regions with lower production costs and environmental regulations. These dependencies are especially dangerous when they affect critical medicines—products for which no suitable alternatives exist and whose absence can result in serious harm to patients.
Multiple root causes contribute to the fragility of the pharmaceutical supply chain. These include underinvestment in European manufacturing facilities, fragmented procurement strategies among Member States and a growing shortage of specialised workforce in pharmaceutical production. Additionally, market dynamics favouring low-cost procurement have disincentivised investments in essential but less profitable generic medicines. The Union’s exposure is further aggravated by export restrictions and supply disruptions during crises, revealing how essential economic security is intertwined with public health preparedness.
Strategic Regulation to Boost Manufacturing and Coordination
To address these challenges, the proposed Regulation introduces several key structural measures. First, it builds upon the Union List of Critical Medicines, identifying over 270 active substances crucial to public health. This list is used as a basis for evaluating vulnerabilities and prioritising action. The proposal promotes investment in manufacturing capacities for these substances within the EU, aiming to reduce reliance on single-source suppliers and boost overall resilience.
One of the Regulation’s innovative mechanisms is the designation of "Strategic Projects"—initiatives that meet specific criteria related to public health impact and supply chain vulnerability. These projects will benefit from fast-tracked permitting processes, targeted financial incentives and regulatory support. Additionally, national and EU-level funding mechanisms, including EU4Health and Horizon Europe, are aligned to support the scaling and modernisation of manufacturing infrastructure for critical medicines and their key inputs.
Moreover, to harmonise procurement and mitigate market fragmentation, the Regulation proposes enhanced collaborative procurement frameworks. By aggregating demand and applying the “most economically advantageous tender” (MEAT) criteria, Member States are encouraged to prioritise supply chain resilience and manufacturing origin over cost alone. These actions aim to create a predictable and investment-friendly environment, thus fostering innovation and strategic autonomy in the pharmaceutical sector.
Related Read: Strengthening Healthcare Supply Chain Resilience
Collaborative Governance and International Partnerships
Effective implementation of this framework requires coordinated governance and international outreach. To this end, the Regulation proposes the establishment of the Critical Medicines Coordination Group. This body will guide strategic decisions, evaluate funding proposals and facilitate procurement cooperation between Member States. It will also oversee the execution of national programmes that align procurement and reimbursement strategies with the broader EU objectives of security and accessibility.
Recognising the global nature of pharmaceutical supply chains, the proposal emphasises the importance of strategic international partnerships. The Commission is tasked with identifying non-EU countries that can support diversification goals while maintaining high standards of safety and reliability. This international dimension complements efforts within the EU by ensuring flexibility and reducing bottlenecks in raw material sourcing and production.
The Regulation’s commitment to data-driven policymaking is also evident. It builds on existing data collection and monitoring platforms, including the European Shortages Monitoring Platform, to ensure real-time tracking of medicine availability and vulnerabilities. These insights will inform policy adjustments and ensure transparency in evaluating the effectiveness of implemented measures.
The proposed Critical Medicines Regulation marks a pivotal shift in the EU’s approach to pharmaceutical security. By addressing long-standing industrial, regulatory and geopolitical challenges, it aims to ensure the continuous availability of critical medicines for all European citizens. Its balanced blend of incentives, coordination and strategic planning reflects a broader vision of a resilient and autonomous healthcare system. As Europe prepares for future health and economic shocks, this regulation will be instrumental in reinforcing the foundation of the European Health Union and securing the integrity of its public health infrastructure.
Source: European Commission
Image Credit: iStock
